All News

psoriatic.PIP_.JPG

Secukinumab Better than Adalimumab - Maybe?

d Jack Cush, MD

The EXCEED study was a head-to-head trial of secukinumab (SEC) versus adalimumab (ADA) as first-line monotherapy in psoriatic arthritis (PsA) patients; this 52 week trial showed that while SEC failed to achieve clinical superiority over ADA, SEC treated patients demonstrated higher

Read Article
podcastLogo-01%20RESIZED.jpg

RheumNow Podcast – The Beat Goes On (5.8.20)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com.

Read Article
Clot.DVT_.VTE_.blood_.jpg

COVID-19 and Thrombotic Complications

d Jack Cush, MD

Severe and fatal outcomes with coronavirus infection are often the result of the downstream damage that follows the viral infection.

Read Article
exercise.shoes_.jpg

Physical Activity Prevents Hospitalization

d Jack Cush, MD

Modifiable lifestyle choices can impact long term health.  A recent study shows that usual and increased physical activity can results in less hospitalization amongst the the general population.

Read Article
1194 participants in Osteoarthritis Initiative shows 10 yr risk of incident Xray Knee OA was not increased by long term sitting, low-moderate physical activity (adjOR 0.69; 0.48-1.01) or strenuous phys activity (aOR 0.75; 0.53-1.07) https://t.co/7pCOwLpscr

Links:

Dr. John Cush RheumNow ( View Tweet)

"There's a rule in acting called "Don't play the result." If you have a character who's going to end up in a certain place, don't play that until you get there. Play each scene and each beat as it comes. And that's what you do in life: You don't play the result." -Michael J. Fox

Dr. John Cush RheumNow ( View Tweet)

Why are more MEN (severely?) affected in COVID-19? Men have higher levels of circulating ACE2 (unrelated to ACEi or ARB HTN meds) based on a Biobank study of 1485 men, 537 women. ACE2 is found in lungs, heart, kidneys, vessels & testes https://t.co/CWXevTNYWm

Links:

Dr. John Cush RheumNow ( View Tweet)

Anakinra studied in COVID(+) ARDS (nonICU) pts w/ high CRP L or ferritin; 29 high dose Anakinra vs 17 controls. At day 21, more survival with anakinra 90% vs. Controls 56% (p=0·009). Anakinra also more improved CRP+resp function (72 vs 50%) https://t.co/wxjlQG44Oc

Links:

Dr. John Cush RheumNow ( View Tweet)

The RheumNow Podcast is up - The Beat Goes On.... anakinra, nr-AxSpA, Smoking & GPA, PSS guidelines, IFNa, COVID and IL-6, HCQ,QTc, and Thromboses https://t.co/BsaALcHclv

Links:

Dr. John Cush RheumNow ( View Tweet)

European Medicines Agency (EMA), FDA and Health Canada have all issued warnings about the use of hydroxychloroquine & chloroquine in coronavirus, stating they should only be used in drug studies or hospitalized pts. https://t.co/HT39sT31Rq

Links:

Dr. John Cush RheumNow ( View Tweet)

American Hospital Association (AHA), in a new report, projected a loss of $202.6 billion from COVID-19 expenses and lost revenue for US hospitals and health systems from Mar 1 to Jun 30—about $50 billion in losses each month. https://t.co/pidOduwnDb

Links:

Dr. John Cush RheumNow ( View Tweet)

Anakinra works in CPPD. Metanalysis of biologics use finds 74 pts Rx with anakinra for refractory dz (85%) or w/ contraindications (23%). Anakinra resp seen in 81% of acute and 43% of chronic CPPD pts. Few adverse events reported (4.1%) https://t.co/PwJO4ta6i7

Links:

Dr. John Cush RheumNow ( View Tweet)

COVID-19 Does alot of Damage via thrombotic complications - a role for complement or autoantibody mediated thrombotic microangiopathy? #COVID19 https://t.co/33R8WxE5C0

Links:

Dr. John Cush RheumNow ( View Tweet)

Grand Rounds tomorrow at Rutgers - Im Lecturing on “Disease Modifying and Biologic Use for COVID-19 & the Cytokine Storm Syndrome” https://t.co/FYsr77a68Z Meeting ID: 934 0443 3549

Links:

Dr. John Cush RheumNow ( View Tweet)

Random thought about virtual clinics. Beginning to think that phone just as good as a stop gap as video. Less performative, more relaxed, and less tiring. Rheumatology is mainly (mainly) about history esp for those patients you know well.

Ronan Kavanagh RonanTKavanagh ( View Tweet)

“Middle-high level of RF-IgM could lead to false-positive reactivity of SARS-CoV-2 IgM “ As more people want SARS-CoV2 antibody testing, I am afraid this will give people a false sense of security ⁦@RheumNow⁩ ⁦@ACRheum⁩ NCBI - NLM - NIH https://t.co/vkjWRJQV27

Links:

k dao KDAO2011 ( View Tweet)

Check out a great Grand Rounds by Dr. Len Calabrese @LCalabreseDO on "IL-6 in Health & Disease" - great 30 min lecture and great Q&A session - Bravo Lenny! https://t.co/eWTKotQya3

Links:

Dr. John Cush RheumNow ( View Tweet)

Case report of a stable GPA patient treated with pred and Rituxan on 3/5, developed COVID Sxs next day, progressed to high fever, resp failue, mech ventilaion, Rx with antivirals, HCQ; extubated day 20, negative PCR x2 and discharged day 29. https://t.co/SSSKRbYK2R

Links:

Dr. John Cush RheumNow ( View Tweet)

Italian study of 1193 Psoriasis pts, there were 17 biologic (TNF, UST, IL17 IL23) treated COVID cases. When compared to 19 local nonPSO/Nonbiologic pts. PsO had more Sxs (OR 3.4), more hospitalizations (OR 3.6), but no difference in ICU admission or death https://t.co/6LR857Ksdk

Links:

Dr. John Cush RheumNow ( View Tweet)

5 reasons Telehealth is here to stay: 1) Fast adoption fostered by technology; 2) Lowered regulatory hurdles; 3) Improved financial reimbursements; 4) Video Telehealth can be built upon; & 5) Untapped potential with adoption by Pts and MDs https://t.co/UMeRyUtKnK

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×